Diaceutics’ (DXRX) “Buy” Rating Reaffirmed at Canaccord Genuity Group

Diaceutics (LON:DXRX)‘s stock had its “buy” rating reiterated by equities researchers at Canaccord Genuity Group in a research note issued to investors on Tuesday, Marketbeat Ratings reports. They currently have a GBX 160 ($2.01) price target on the stock. Canaccord Genuity Group’s price objective indicates a potential upside of 32.78% from the company’s current price.

Diaceutics Stock Performance

Shares of DXRX opened at GBX 120.50 ($1.51) on Tuesday. The firm has a market capitalization of £101.79 million, a PE ratio of -4,016.67 and a beta of 0.58. The company has a quick ratio of 9.92, a current ratio of 4.85 and a debt-to-equity ratio of 2.93. The firm has a 50-day moving average price of GBX 121.99 and a 200 day moving average price of GBX 126.21. Diaceutics has a 52-week low of GBX 84.50 ($1.06) and a 52-week high of GBX 136 ($1.71).

Diaceutics Company Profile

Diaceutics PLC, a diagnostic commercialisation company, provides data, data analytics, and implementation services for pharmaceutical companies worldwide. It operates DXRX platform, which offers DXRX data solutions, including access to various pipelines of diagnostic testing data from a network of laboratories that provides DXRX signal, lab mapping, testing dashboard, and physician mapping services; DXRX marketplace solutions, which enables a marketplace, where labs, pharma, and diagnostic companies come to find partners for collaborations on precision medicine diagnostics.